XML 20 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating expenses:    
Research and development expenses $ 434 $ 492
General and administrative expenses (Note 14a) 2,008 2,678
Operating loss (2,442) (3,170)
Financial expense, net (Note 14b) (2,487) (280)
Net loss (4,929) (3,450)
Addition to net loss (for EPS purpose)    
Deemed dividend with respect to the repurchase of right for future investment (185)
Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants (267)
Deemed dividend due to exercise price adjustment of warrants (390)
Net loss applicable to stockholders of Common Stock (5,319) (3,902)
Comprehensive loss $ (4,929) $ (3,450)
Basic and diluted net loss per share $ (0.32) $ (0.36)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share 16,669,628 10,519,682